全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用：99美元
投递稿件

查看量下载量

相关文章

更多...

卡双平治疗新诊断2型糖尿病患者的疗效及安全性研究
Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Therapy in Treating Patients with Newly Diagnosed T2DM

DOI: 10.12677/ACM.2020.109281, PP. 1869-1873

Keywords: 2型糖尿病，吡格列酮二甲双胍，血糖，糖化血红蛋白
T2DM, Pioglitazone/Metformin Fixed-Dose Combination, Glycemic, HbA1c

Full-Text   Cite this paper   Add to My Lib

Abstract:

目的：观察卡双平(吡格列酮二甲双胍)治疗新诊断2型糖尿病(type 2 diabetes mellitus, T2DM)患者的疗效及安全性。方法：选取35例新诊断的T2DM患者，观察卡双平治疗12周后糖化血红蛋白(hemoglobin A1c，HbA1c)及空腹血糖(fasting plasma glucose, FPG)的变化，明确药物的疗效及不良反应。结果：经过卡双平12周治疗后，新诊断的T2DM患者HbA1c及FPG水平明显下降(P < 0.05)，而且没有严重不良反应发生(P > 0.05)。结论：卡双平治疗新诊断的T2DM患者疗效确切，不良反应发生率低，可作为新诊断T2DM患者的治疗方案之一。
Objective: To examine the efficacy and safety of pioglitazone/metformin fixed-dose combination therapy in a twice-daily regimen over 12 weeks treatment in newly diagnosed T2DM patients. Methods: 35 cases newly diagnosed T2DM patients were recruited. The changes of HbA1c, FPG and adverse events were evaluated at 12 weeks. Results: After 12 weeks treatment, HbA1c and FPG were significantly decreased compared with baseline. The pioglitazone/metformin fixed-dose combination was well tolerated with no unexpected findings in adverse events. Conclusions: The pioglitazone/metformin fixed-dose combination exhibits an excellent efficacy and safety for T2DM, which is a selection for those patients with newly diagnosed T2DM.

References

[1]  UK Prospective Diabetes Study Group (1998) Intensive Blood-Glucose Control with Sulphonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33). The Lancet, 352, 837-853.
https://doi.org/10.1016/S0140-6736(98)07019-6
[2]  UK Prospective Diabetes Study Group (1998) Effect of Intensive Blood-Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34). The Lancet, 352, 854-865.
https://doi.org/10.1016/S0140-6736(98)07037-8
[3]  Stratton, M.I. (2000) Association of Glycaemia with Macrovascular and Microvascular Complications of Type 2 Diabetes (UKPDS 35): Prospective Observational Study. BMJ, 321, 405-412.
https://doi.org/10.1136/bmj.321.7258.405
[4]  Holman, R.R., Paul, S.K., Angelyn Bethel, M., et al. (2008) 10-Year Follow-Up of Intensive Glucose Control in Type 2 Diabetes. New England Journal of Medicine, 359, 1577-1589.
https://doi.org/10.1056/NEJMoa0806470
[5]  Lee, G., Oh, S.-W., Hwang, S.-S., Yoon, J.W., Kang, S.C., Joh, H.-K., Kwon, H., Kim, J. and Park, D. (2017) Comparative Effectiveness of Oral Antidiabetic Drugs in Preventing Cardiovascular Mortality and Morbidity: A Network Meta-Analysis. PLoS ONE, 12, e0177646.
https://doi.org/10.1371/journal.pone.0177646
[6]  朱大龙, 母义明, 翁建平, 等. 吡格列酮二甲双胍复方制剂临床应用专家建议[J]. 中国糖尿病杂志, 2017, 25(12): 1057-1063.
[7]  中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中国实用内科杂志, 2018, 38(4): 292-344.
[8]  Jellinger, P.S., Handelsman, Y., Rosenblit, P.D., et al. (2017) American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease. Endocrine Practice, 23, 1-87.
https://doi.org/10.4158/EP171764.APPGL
[9]  Derosa, G., Maffioli, P., Salvadeo, S.A.T., et al. (2009) Direct Comparison among Oral Hypoglycemic Agents and Their Association with Insulin Resistance Evaluated by Euglycemic Hyperinsulinemic Clamp: The 60’s Study. Metabolism, 58, 1059-1066.
https://doi.org/10.1016/j.metabol.2009.03.007
[10]  Perez, A., Zhao, Z., Jacks, R. and Spanheimer, R. (2009) Efficacy and Safety of Pioglitazone/Metformin Fixed-Dose Combination Therapy Compared with Pioglitazone and Metformin Monotherapy in Treating Patients with T2DM. Current Medical Research & Opinion, 25, 2915-2923.
https://doi.org/10.1185/03007990903350011
[11]  Einhorn, D., Rendell, M., Rosenzweig, J., et al. (2000) Pioglitazone Hydrochloride in Combination with Metformin in the Treatment of Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Study. Clinical Therapeutics, 22, 1395-1409.
https://doi.org/10.1016/S0149-2918(00)83039-8
[12]  Perez, A., Jacks, R., Arora, V. and Spanheimer, R. (2010) Effects of Pioglitazone and Metformin Fixed-Dose Combination Therapy on Cardiovascular Risk Markers of Inflammation and Lipid Profile Compared with Pioglitazone and Metformin Monotherapy in Patients with Type 2 Diabetes. Journal of Clinical Hypertension, 12, 973-982.
https://doi.org/10.1111/j.1751-7176.2010.00389.x
[13]  Andreas, P., Nikolaus, M., Georg, L., Langenfeld, M., Walcher, D., Konrad, T. and Forst, T. (2005) Improvement of Cardiovascular Risk Markers by Pioglitazone Is Independent from Glycemic Control: Results from the Pioneer Study. Journal of the American College of Cardiology, 45, 1925-1931.
https://doi.org/10.1016/j.jacc.2005.03.041
[14]  Mazzone, T., Meyer, P.M., Feinstein, S.B., et al. (2006) Effect of Pioglitazone Compared with Glimepiride on Carotid Intima-Media Thickness in Type 2 Diabetes: A Randomized Trial. JAMA, 296, 2572-2581.
https://doi.org/10.1001/jama.296.21.joc60158
[15]  Chu, N.V., Kong, A.P.S., Kim, D.D., et al. (2002) Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients with Type 2 Diabetes. Diabetes Care, 25, 542-549.
https://doi.org/10.2337/diacare.25.3.542

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133